公开(公告)号：US20240082218A1

公开(公告)日：2024-03-14

申请号：US18267735

申请日：2021-12-20

Applicant: NOVARTIS AG

Inventor： Vasileios ASKOXYLAKIS ,  Saskia Maria BRACHMANN ,  Simona COTESTA ,  Xiaoming CUI ,  Jeffrey ENGELMAN ,  Anna FARAGO ,  Marc GERSPACHER ,  Diana GRAUS PORTA ,  Catherine LEBLANC ,  Edwige Liliane Jeanne LORTHIOIS ,  Bo LIU ,  Rainer MACHAUER ,  Robert MAH ,  Christophe MURA ,  Pascal RIGOLLIER ,  Nadine SCHNEIDER ,  Stefan STUTZ ,  Andrea Helga Emmi VAUPEL ,  Nicolas WARIN ,  Andreas WEISS ,  Rainer WILCKEN ,  Padmaja YERRAMILLI-RAO

IPC: A61K31/416 ,  A61K9/00 ,  A61K31/497 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K9/0053 ,  A61K31/497 ,  A61K39/3955 ,  A61P35/00

Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.

公开(公告)号：US20230181756A1

公开(公告)日：2023-06-15

申请号：US17997137

申请日：2021-04-11

Applicant: Novartis AG

Inventor： Vasileios ASKOXYLAKIS ,  Michelle COULSON ,  Anhthu DANG ,  Yuyan DUAN ,  Jessica MAKOFSKE ,  Sabine ROTTMANN ,  Xiaoli WANG

IPC: A61K47/68 ,  A61K45/06 ,  C07K16/28 ,  A61K9/00 ,  A61P35/00 ,  A61K38/12

CPC classification number: A61K47/6867 ,  A61K45/06 ,  C07K16/2866 ,  A61K9/0019 ,  A61P35/00 ,  A61K38/12

Abstract: This application discloses compositions and methods of treating follicular lymphoma using CCR7 antibody drug conjugates. Also disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to said subject an antibody drug conjugate, wherein the cancer expresses CCR7, wherein the antibody drug conjugate is administered to said subject at about 0.1 mg/kg to about 10 mg/kg.

公开(公告)号：US20190211110A1

公开(公告)日：2019-07-11

申请号：US15535405

申请日：2015-12-10

Applicant: MASSACHUSETTS GENERAL HOSPITAL ,  NOVARTIS AG

Inventor： Qing SHENG ,  Rakesh K. JAIN ,  Vasileios ASKOXYLAKIS ,  Gino B. FERRARO ,  Dai FUKUMURA ,  David P. KODACK

IPC: C07K16/32 ,  A61P35/04 ,  A61K39/395 ,  A61K31/5377

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.